Satellite Symposia
The Satellite Symposia are industry-sponsored, CME-certified programs offered in conjunction with ASH specialty meetings. These events are offered in conjunction with the 2024 Highlights of ASH in Asia Pacific and are not part of the official ASH meeting programming and are planned solely by the sponsoring company. There is no fee to attend and registration to HOA is not required to participate.
The 2024 Satellite Symposia are each presented in-person, once, live at the date, time, and location listed. To register, click the “Register” button below each title in the schedule. Check back as registration links and details will continue to be added as managing companies share them with ASH. For program-specific questions, please reach out to the managing company contact listed below each session.
Novo Nordisk
Addressing the Challenges of Inhibitors in Haemophilia: A New Era in Non-Factor Replacement Therapy
February 16, 2024, 6:00 p.m. to 7:00 p.m. Registration and Refreshments begin at 5:45 p.m.
International Convention Centre Sydney Meeting Rooms C3.4 and C3.5
In an evolving haemophilia landscape, therapeutic advancements are being made across all haemophilia subtypes, addressing unmet needs, especially in haemophilia with inhibitors. This expert-led symposium will discuss:
- The potential value of different classes of non-factor replacement therapy
- Anti-TFPi as an emerging class of treatment
- The effect of Anti-TFPi treatment on prophylaxis on target joint resolution
Speaker Information
Dr. Liane Khoo is the Haemophilia Treatment Centre Director at the Royal Prince Alfred Hospital in Sydney, NSW, Australia. Dr. Khoo is actively involved in numerous clinical trials for haemophilia, including gene therapy, non-factor replacements, extended half-life factor replacements. She has a keen interest in laboratory aspects related to haemophilia care.
Professor Tran is Head of Thrombosis and Haemostasis Services, and Director of the Haemophilia Treatment Centre at Alfred Health. He is a clinical Professor at the Australian Centre for Blood Diseases (ACBD), Central Clinical School, Monash University. He is Chair of the Clinical Trials group of The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) and former Chair of the Australian Haemophilia Centre Directors’ Organisation (AHCDO). He is a clinical research haematologist who has a strong national & international reputation in the field of thrombosis and haemostasis. He's well published with over 120 peer-reviewed publications and more than 3500 citations.
Additional Information
If you would like further information, please contact:
Lida Derakhshan
0418 249 054
[email protected]
Prothena
Unfolding Advanced Light Chain (AL) Amyloidosis: From Diagnostic Challenges to Emerging Therapies
February 16, 2024, 6:00 p.m. to 7:00 p.m. Registration and Refreshments begin at 5:45 p.m.
International Convention Centre Sydney Meeting Rooms C2.2 and C2.3
Join our expert, Dr. Angie Yong, as she discusses the most pressing topics in light chain (AL) amyloidosis. Dr. Yong will review unmet needs in patients with advanced AL amyloidosis and summarize prevalent diagnostic obstacles. Ongoing clinical trials of investigational amyloid-depleting therapies aiming to improve early mortality in patients with advanced AL amyloidosis will also be discussed. The audience will have an opportunity to ask questions at the end of the session.
Additional Information
If you would like further information, please contact:
Lauren Vosseller
[email protected]
AstraZeneca
How I approach CLL and MCL Treatment in the Era of Novel Therapies (an Australian View)
February 16, 2024, 5:30 p.m. to 7:00 p.m.
W Hotel, Darling Harbour, The Great Room 1
An expert panel of 4 Australian Haematoloigsts will share how they personally approach the treatment of CLL and MCL during an era of novel therapies. Each panelist will share a case study and discuss relevant data and treatment options. This will be an interactive session and challenge your clinical thinking.
Speaker Information
Dr. Xavier Badoux (Chair), Associate Professor Mary Ann Anderson, Dr. Sasanka Handunnetti and Dr. Jock Simpson
Additional Information
If you would like further information, please contact:
Gretchen Hamilton
[email protected]
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission